Advertisement

Parkinson Disease Therapies and Drugs

  • Rodolphe Hajj
Chapter

Abstract

Two centuries after its first description, Parkinson’s is still classified among the diseases with serious unmet medical needs. Despite the approval of several symptomatic drugs for its management, Parkinson disease progression is today unavoidable. Life expectancies vary considerably between patients and principally depend on the occurrence of secondary incidents during life, as the disease is not deadly by itself. Besides supportive therapies and neurosurgeries, drug therapies for Parkinson disease consist in six general families: l-Dopa, decarboxylase inhibitors, catechol-O-methyltransferase inhibitors, monoamine oxidase inhibitors, dopamine agonists and other non-dopaminergic therapies. The choice between these treatments depends on the patient’s lifestyle and the age of onset of the disease, but the final decision is made collaboratively by the physician and the patient. Nevertheless, l-Dopa is still the most widely prescribed medication. In this chapter, I will summarize the currently established pharmacotherapy for Parkinson disease, describe the common treatment strategies and give few examples of drugs that are still ongoing research and development. Finally, I will focus on combination therapy as the next generation and necessary option for the treatment and cure of this debilitating disease.

Keywords

Parkinson disease Parkinson therapy Parkinson drugs Drug repurposing Drug combinations 

References

  1. 1.
    Beaulieu J-M, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63:182–217.  https://doi.org/10.1124/pr.110.002642.CrossRefGoogle Scholar
  2. 2.
    Toulorge D, Schapira AHV, Hajj R. Molecular changes in the postmortem parkinsonian brain. J Neurochem. 2016;139(Suppl 1):27–58.  https://doi.org/10.1111/jnc.13696.CrossRefPubMedGoogle Scholar
  3. 3.
    Xia R, Mao Z-H. Progression of motor symptoms in Parkinson’s disease. Neurosci Bull. 2012;28:39–48.  https://doi.org/10.1007/s12264-012-1050-z.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Garcia-Ruiz PJ, Chaudhuri KR, Martinez-Martin P. Non-motor symptoms of Parkinson’s disease a review…from the past. J Neurol Sci. 2014;338:30–3.  https://doi.org/10.1016/j.jns.2014.01.002.CrossRefPubMedGoogle Scholar
  5. 5.
    Olanow CW, Schapira AHV. Therapeutic prospects for Parkinson disease. Ann Neurol. 2013;74:337–47.  https://doi.org/10.1002/ana.24011.CrossRefPubMedGoogle Scholar
  6. 6.
    Schapira AH, Agid Y, Barone P, Jenner P, Lemke MR, Poewe W, Rascol O, Reichmann H, Tolosa E. Perspectives on recent advances in the understanding and treatment of Parkinson’s disease. Eur J Neurol. 2009;16:1090–9.  https://doi.org/10.1111/j.1468-1331.2009.02793.x.CrossRefPubMedGoogle Scholar
  7. 7.
    Dorszewska J, Prendecki M, Lianeri M, Kozubski W. Molecular effects of L-dopa therapy in Parkinson’s disease. Curr Genomics. 2014;15:11–7.  https://doi.org/10.2174/1389202914666131210213042.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196–205.  https://doi.org/10.1016/S0140-6736(14)60683-8.CrossRefGoogle Scholar
  9. 9.
    Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–9.  https://doi.org/10.1016/S1474-4422(13)70293-X.CrossRefPubMedGoogle Scholar
  10. 10.
    Hwang O. Role of oxidative stress in Parkinson’s disease. Exp Neurobiol. 2013;22:11–7.  https://doi.org/10.5607/en.2013.22.1.11.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. N Engl J Med. 1989;321:1364–71.  https://doi.org/10.1056/NEJM198911163212004.CrossRefGoogle Scholar
  12. 12.
    Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: neuroprotective strategies and alternative therapies for parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:976–82.  https://doi.org/10.1212/01.wnl.0000206363.57955.1b.CrossRefPubMedGoogle Scholar
  13. 13.
    Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361(13):1268–78.  https://doi.org/10.1056/NEJMoa0809335.CrossRefPubMedGoogle Scholar
  14. 14.
    Müller T. Emerging approaches in Parkinson’s disease—adjunctive role of safinamide. Ther Clin Risk Manag. 2016;12:1151–60.  https://doi.org/10.2147/TCRM.S86393.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord. 2006;21:343–53.  https://doi.org/10.1002/mds.20724.CrossRefPubMedGoogle Scholar
  16. 16.
    Montastruc F, Moulis F, Araujo M, Chebane L, Rascol O, Montastruc J-L. Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson’s disease. Eur J Clin Pharmacol. 2017;73(1):99–103.  https://doi.org/10.1007/s00228-016-2142-x.CrossRefPubMedGoogle Scholar
  17. 17.
    Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20:5–15.  https://doi.org/10.1111/j.1468-1331.2012.03866.x.CrossRefPubMedGoogle Scholar
  18. 18.
    Stayte S, Vissel B. Advances in non-dopaminergic treatments for Parkinson’s disease. Front Neurosci. 2014;8:1–29.  https://doi.org/10.3389/fnins.2014.00113.CrossRefGoogle Scholar
  19. 19.
    Schapira AHV, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, et al. Novel pharmacological targets for the treatment of Parkinson’s disease. Nat Rev Drug Discov. 2006;5:845–54.  https://doi.org/10.1038/nrd2087.CrossRefPubMedGoogle Scholar
  20. 20.
    Nagatsua T, Sawadab M. L-dopa therapy for Parkinson’s disease: past, present, and future. Parkinsonism Relat Disord. 2009;15(Suppl 1):S3–8.  https://doi.org/10.1016/S1353-8020(09)70004-5.CrossRefPubMedGoogle Scholar
  21. 21.
    Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs. 2010;24:941–68.  https://doi.org/10.2165/11537810-000000000-00000.CrossRefPubMedGoogle Scholar
  22. 22.
    Ainsworth C. Networking for new drugs. Nat Med. 2011;17:1166–8.  https://doi.org/10.1038/nm1011-1166.CrossRefPubMedGoogle Scholar
  23. 23.
    Chumakov I, Milet A, Cholet N, Primas G, Boucard A, Pereira Y, Graudens E, et al. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J Rare Dis. 2014;9:201.  https://doi.org/10.1186/s13023-014-0201-x.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chumakov I, Nabirotchkin S, Cholet N, Milet A, Boucard A, Toulorge D, Pereira Y, et al. Combining two repurposed drugs as a promising approach for Alzheimer’s disease therapy. Sci Rep. 2015;5:7608.  https://doi.org/10.1038/srep07608.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hajj R, Milet A, Toulorge D, Cholet N, Laffaire J. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease. Sci Rep. 2015;5:16084.  https://doi.org/10.1038/srep16084.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wichmann T, Dostrovsky JO. Pathological basal ganglia activity in movement disorders. Neuroscience. 2011;198:232–44.  https://doi.org/10.1016/j.neuroscience.2011.06.048.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cotzias GC, Papavasiliou PS, Gellene R. L-dopa in Parkinson’s syndrome. N Engl J Med. 1969;281:272.  https://doi.org/10.1056/NEJM196907312810518.CrossRefPubMedGoogle Scholar
  28. 28.
    Rooke EDM, Vesterinen HM, Sena ES, Egan KJ, Macleod MR. Dopamine agonists in animal models of Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17:313–20.  https://doi.org/10.1016/j.parkreldis.2011.02.010.CrossRefPubMedGoogle Scholar
  29. 29.
    Duty S, Jenner P. Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164:1357–91.  https://doi.org/10.1111/j.1476-5381.2011.01426.x.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Experimental Biology and PharmacologyPharnextIssy-Les-MoulineauxFrance

Personalised recommendations